Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Common Equity (2016 - 2025)

Conmed's Common Equity history spans 16 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 7.31% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, up 7.31%, while the annual FY2025 figure was $1.0 billion, 7.31% up from the prior year.
  • Common Equity reached $1.0 billion in Q4 2025 per CNMD's latest filing, up from $1.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.0 billion in Q4 2025 to a low of $673.0 million in Q2 2022.
  • Average Common Equity over 5 years is $837.6 million, with a median of $792.9 million recorded in 2022.
  • Peak YoY movement for Common Equity: fell 9.61% in 2022, then rose 17.17% in 2024.
  • A 5-year view of Common Equity shows it stood at $785.4 million in 2021, then decreased by 5.08% to $745.5 million in 2022, then rose by 11.89% to $834.2 million in 2023, then rose by 15.4% to $962.7 million in 2024, then grew by 7.31% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for CNMD's Common Equity are $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025).